注射毒品女性中长效注射剂与口服艾滋病病毒暴露前预防的优先启动情况
Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs.
作者信息
Roth Alexis M, Bartholomew Tyler S, Ward Kathleen M, Groves Allison, Mazzella Silvana, Bellamy Scarlett, Amico K Rivet, Carrico Adam W, Ironson Gail, Krakower Douglas
机构信息
Department of Community Health and Prevention, Drexel University, Dornsife School of Public Health, Philadelphia, Pennsylvania, USA.
Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.
出版信息
Clin Infect Dis. 2025 Mar 17;80(3):621-625. doi: 10.1093/cid/ciae450.
Abstract
Fifty-five of 62 women who inject drugs (WWID) selected long-acting cabotegravir (CAB-LA) over oral PrEP, and 51/55 received a first injection. More recent injection drug use and number of sexual partners were associated with selecting CAB-LA (P < .05). Findings provide preliminary evidence of a strong preference for longer-acting products among WWID.
摘要
62名注射毒品的女性（WWID）中有55人选择长效卡博特韦（CAB-LA）而非口服暴露前预防药物（PrEP），其中51/55人接受了首次注射。近期的注射吸毒情况和性伴侣数量与选择CAB-LA有关（P < 0.05）。研究结果为WWID对长效产品有强烈偏好提供了初步证据。
相似文献
1
Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs.注射毒品女性中长效注射剂与口服艾滋病病毒暴露前预防的优先启动情况
Clin Infect Dis. 2025 Mar 17;80(3):621-625. doi: 10.1093/cid/ciae450.
2
Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis.南非针对青春期女孩和年轻女性的长效注射用艾滋病毒暴露前预防药物的成本效益定价：基于模型的分析
Lancet Glob Health. 2025 May 26. doi: 10.1016/S2214-109X(25)00119-6.
3
PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study.南非开普敦孕妇和哺乳期妇女对注射用卡博特韦的暴露前预防偏好及早期可接受性：“准备好选择”研究的结果
J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26492. doi: 10.1002/jia2.26492.
4
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trial.长效注射用卡博特韦用于顺性别女性青少年预防HIV的安全性、耐受性和可接受性（HPTN 084-01）：一项单臂、开放标签的2b期试验
Lancet HIV. 2025 Apr;12(4):e252-e260. doi: 10.1016/S2352-3018(24)00310-2. Epub 2025 Mar 12.
5
Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB-Brasil study.探索对暴露前预防（PrEP）选择及移动健康干预措施的认知和偏好：来自巴西ImPrEP社区咨询委员会（CAB）研究的见解
J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26493. doi: 10.1002/jia2.26493.
6
Awareness and intention to use event-driven and long-acting injectable pre-exposure prophylaxis among adolescent and young men who have sex with men and transgender women in Brazil: a cross-sectional study.巴西男男性行为者和跨性别女性中青少年对事件驱动型和长效注射用暴露前预防药物的知晓率及使用意愿：一项横断面研究
J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26479. doi: 10.1002/jia2.26479.
7
Strategies for implementing long-acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study.在美国为黑人女性服务的诊所中实施长效卡博特韦用于暴露前预防的策略：EBONI研究中医疗保健提供者的中期结果
J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26497. doi: 10.1002/jia2.26497.
8
Feasibility and acceptability of persons on long-acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study.在肯尼亚农村和乌干达开展的SEARCH动态选择HIV预防试验扩展研究中，长效卡博特韦用于HIV预防的可行性及可接受性：一项纵向队列研究
J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26465. doi: 10.1002/jia2.26465.
9
PrEP15-19 Choices: an implementation study protocol of HIV prevention with oral and long-acting injectable cabotegravir PrEP in real-word settings among sexual and gender minority adolescents in Brazil.PrEP15 - 19选择：一项在巴西性少数和性别少数青少年的现实环境中使用口服和长效注射卡博特韦进行HIV预防的实施研究方案。
BMJ Open. 2025 Jan 20;15(1):e083146. doi: 10.1136/bmjopen-2023-083146.
10
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.接受注射用卡博特韦预防艾滋病毒的男同性恋和顺性别男性及跨性别女性中人类免疫缺陷病毒（HIV）感染的特征：HPTN 083研究
J Infect Dis. 2021 Nov 16;224(9):1581-1592. doi: 10.1093/infdis/jiab152.
本文引用的文献
1
Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.系统评价关于使用注射用暴露前预防措施预防 HIV 感染的价值观和偏好。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26107. doi: 10.1002/jia2.26107.
2
Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.注射吸毒人群中 HIV 和丙型肝炎病毒的感染率，以及与年龄、性别或性别认同的相关性：一项全球系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):533-552. doi: 10.1016/S2468-1253(23)00018-3. Epub 2023 Mar 27.
3
Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use.有商业保险且可能有注射吸毒行为者的 HIV 暴露前预防用药开具情况的流行率。
JAMA Netw Open. 2022 Jul 1;5(7):e2221346. doi: 10.1001/jamanetworkopen.2022.21346.
4
Estimated Number of People Who Inject Drugs in the United States.美国注射吸毒者人数估计。
Clin Infect Dis. 2023 Jan 6;76(1):96-102. doi: 10.1093/cid/ciac543.
5
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.卡博特韦用于女性艾滋病毒 1 型的预防：来自 HPTN 084 的结果，一项 3 期、随机临床试验。
Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1.
6
An Experimental Study of the Effects of Patient Race, Sexual Orientation, and Injection Drug Use on Providers' PrEP-Related Clinical Judgments.患者种族、性取向和注射吸毒对提供者的 PrEP 相关临床判断的影响的实验研究。
AIDS Behav. 2022 May;26(5):1393-1421. doi: 10.1007/s10461-021-03495-3. Epub 2021 Nov 9.
7
Syringe Services Programs' Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them.注射器服务项目在美国终结艾滋病流行中的作用：没有它们我们无法实现这一目标。
Am J Prev Med. 2021 Nov;61(5 Suppl 1):S118-S129. doi: 10.1016/j.amepre.2021.05.044.
8
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.长效注射用卡替拉韦在未感染 HIV 的成年人中的尾部阶段安全性、耐受性和药代动力学：HPTN 077 试验的二次分析。
Lancet HIV. 2020 Jul;7(7):e472-e481. doi: 10.1016/S2352-3018(20)30106-5. Epub 2020 Jun 1.
9
Buprenorphine Treatment for Opioid Use Disorder: An Overview.阿片类物质使用障碍的丁丙诺啡治疗：概述。
CNS Drugs. 2019 Jun;33(6):567-580. doi: 10.1007/s40263-019-00637-z.
10
Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections.采用荟萃分析估计美国注射毒品人群的数量，以计算全国 HIV 和丙型肝炎病毒感染的发生率。
PLoS One. 2014 May 19;9(5):e97596. doi: 10.1371/journal.pone.0097596. eCollection 2014.
Zotero 插件